This week, while most eyes in the biotech world were on the IPO of gene therapy firm Voyager Therapeutics, an early-stage drug developer called WaVe Life Sciences pulled off an even larger IPO on the other side of Cambridge. Wave (Nasdaq: WVE), a biotech with corporate offices in Alewife but based in Singapore, managed to raise $102 million on Wednesday, the same day that Voyager (Nasdaq: VYGR) was raising $70 million.